Who founded ENB Therapeutics?

ENB Therapeutics was founded by Sumayah Jamal, Robert Schneider in 2018.

Who are ENB Therapeutics's investors?

ENB Therapeutics's investors include BioAdvance, Remiges Ventures, Inc..

How much funding has ENB Therapeutics raised?

ENB Therapeutics has disclosed $9.6M raised across 3 rounds.

Where is ENB Therapeutics headquartered?

ENB Therapeutics is headquartered in New York, US.

ENB Therapeutics

New York, US · Founded 2018 · Delaware corporation · 6 employees on LinkedIn · 2 known investors

Find your way into ENB Therapeutics

123 people in our graph share verified history with the ENB Therapeutics team — schools, employers, funds. One of them is your warm intro.

Walter Olesiakunlockedknows Sumayah Jamal · together at ENB Therapeutics (overlapped)

×7knows the team · via Saint Joseph's University

×2knows the team · via NYU Grossman School of Medicine

×2knows the team · via Icahn School of Medicine at Mount Sinai

ENB Therapeutics develops small molecules targeting the endothelin B receptor (ETBR) in the tumor microenvironment to treat drug-resistant cancers by restoring immune cell infiltration and promoting tertiary lymphoid organ formation. Its preclinical therapies target cancers including melanoma, glioblastoma, squamous cell carcinoma, bladder cancer, and ovarian cancer.

Biotech Healthtech

Founders & leadership

ENB Therapeutics was founded in 2018 by Sumayah Jamal and Robert Schneider.

Sumayah Jamal inPresident, Co-Founder, Chief Scientific OfficerSumayah Jamal is a dermatologist and biochemist with over 30 years of research experience, beginning her work on the endothelin axis in cancer as a postdoctoral fellow in 1997 and later serving as a professor at NYU School of Medicine. She is a co-inventor of patents covering the endothelin B receptor as a cancer therapeutic target and co-founded ENB Therapeutics in 2015, where she serves as President and Chief Scientific Officer.

Robert SchneiderinCo-founder & Chair of Scientific Advisory Board

Sandy Harm inChief Operating OfficerSandy Harm holds advanced degrees in biology, health administration, and health care ethics with a focus on epidemiology and population health. As COO of ENB Therapeutics, Harm brings extensive experience in pharmaceutical R&D operations, clinical research, medical affairs, and project management across oncology and infectious diseases.

Fumitaka MoriNamed on SEC filing

Albert SokolNamed on SEC filing

Board

Barbara SchilbergBoard directorAdvisor & Former CEO at BioAdvance

Investors · 2

BioAdvanceConshohocken · $500K – $1.5M

Remiges Ventures, Inc.Seattle

Reported raises · per SEC filings

Form D private placements

$9.6M disclosed across 3 rounds · 2018–2023

▶$225KraisedOct 2023 · 3 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Sumayah JamalExecutive Officer, Director
Barbara SchilbergDirector
Stuart HwangDirector
Walter OlesiakDirector
Albert SokolExecutive Officer

Offering amount: $1M
Amount sold: $225K
First sale: Sep 2023
Incorporated: Corporation, Delaware, 2018
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$1.3MraisedJan 2021 · 3 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Barbara SchilbergDirector
Albert SokolExecutive Officer
Fumitaka MoriDirector
Sumayah JamalExecutive Officer, Director

Offering amount: $2.6M
Amount sold: $1.3M
First sale: Jan 2021
Incorporated: Corporation, Delaware, 2018
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$8.1MraisedFeb 2020 · 17 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Barbara SchilbergDirector
Fumitaka MoriDirector
Sumayah JamalExecutive Officer, Director
Albert SokolExecutive Officer

Offering amount: $9.1M
Amount sold: $8.1M
First sale: Sep 2018
Incorporated: Corporation, Delaware, 2018
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

Bioworld9 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies competing with ENB Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

ENB Therapeutics to present at the 2023 BIO CEO & Investor and Immuno-Oncology 360o Conferencesbusinesswire.com · Jan 2023

ENB Therapeutics Closes Series A Round of Funding - ANY Seed Fundanyseedfund.com · Sep 2018

Frequently asked questions

What does ENB Therapeutics do?: ENB Therapeutics develops small molecules targeting the endothelin B receptor (ETBR) in the tumor microenvironment to treat drug-resistant cancers by restoring immune cell infiltration and promoting tertiary lymphoid organ formation. Its preclinical therapies target cancers including melanoma, glioblastoma, squamous cell carcinoma, bladder cancer, and ovarian cancer.
Who founded ENB Therapeutics?: ENB Therapeutics was founded by Sumayah Jamal, Robert Schneider in 2018.
Who are ENB Therapeutics's investors?: ENB Therapeutics's investors include BioAdvance, Remiges Ventures, Inc..
How much funding has ENB Therapeutics raised?: ENB Therapeutics has disclosed $9.6M raised across 3 rounds.
Where is ENB Therapeutics headquartered?: ENB Therapeutics is headquartered in New York, US.